The ViennaLab HLA B27 PCR Assays detect the HLA-B*27 allele which is associated ankylosing spondylitis.
HLA-B, as part of the major histocompatibility complex (MHC) class I, is involved in the recognition of self and foreign peptides. The allelic variant HLA-B27 is present in about 8% of healthy Caucasians and is well known as genetic risk factor for spondyloarthropathies. Up to 96% of patients with ankylosing spondylitis (Morbus Bechterew) and up to 80% of patients with reactive arthritis carry the HLAB27 allele. Ankylosing spondylitis is a chronic, inflammatory arthritis that mainly affects spinal joints and the sacroiliac joint. Patients suffer from chronic pain and stiffness in the back and pelvis and, with progressing disease, often develop spinal fusion. The disease usually manifests between 15-30 years of age and is three times more prevalent in males than in females. Often a time period of 5-10 years elapses between early, nonspecific symptoms and a definite diagnosis.
HLA B27 PCR Assays technology
The ViennaLab RealFast™ Assays are based on real-time PCR and hydrolysis probes, also commonly called TaqMan® probes. The sequence-specific oligonucleotide probes carry a fluorescent reporter dye at the 5´-end and a quencher dye at the 3´-end. While the probe is intact, the quencher is close enough to the reporter to suppress the fluorescent signal of the 5´-fluorophore. During the combined annealing/extension phase of PCR, the probe is cleaved by the 5´ to 3´ exonuclease activity of Taq DNA polymerase, thereby separating the fluorophore from the quencher dye. This process results in detectable fluorescence, which is proportional to the amount of accumulated PCR product.
HLA B27 RealFast ™ RT-PCR Assays
|HLA-B27 RealFast™ Assay||7-620||100 tests||detects the HLA-B*27 allele|